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Related Prevention and Treatment Services:
A Review*
David R. Holtgrave, Ronald 0. Valdiserri & Gary A. West**
Introduction
A comprehensive national program designed to prevent
acquisition/transmission of human immunodeficiency virus (HIV) and
reduce the morbidity and mortality associated with HIV infection and
acquired immune deficiency syndrome (AIDS) must include and
integrate many prevention and treatment activities. These include:
public information programs; counseling, testing, referral and partner
notification services; health education and risk reduction programs, e.g.,
street outreach and community level interventions; early intervention
medical and psychosocial services for HIV seropositive persons;
extended ameliorative medical and psychosocial services for persons
living with AIDS; and biomedical and behavioral research to develop
new curative and preventive therapies.
The delivery of a comprehensive program is resource intensive. In
fiscal year 1992, the U.S. Public Health Service (PHS) budget for HIV
and AIDS related activities (including service provision and research)
was $1.96 billion.1 Of this, 42.9% was directed to the National
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Institutes of Health (NIH), 24.4% to the Centers for Disease Control
and Prevention (CDC), 16.1% to the Health Resources and Services
Administration (HRSA), 12.0% to the Substance Abuse and Mental
Health Services .Administration (SAMHSA), 2 3.7% to the Food and
Drug Administration (FDA) and the rest to other PHS agencies.3
Hellinger has estimated that the 1992 cumulative U.S. cost for treating
all persons with HIV infection (including those living with AIDS) was
$10.3 billion. 4
Although the number of HIV infections and AIDS cases continues
to increase, fiscal resources for delivery of prevention and treatment
services are necessarily finite. In fact, some HIV-related fiscal resources
have recently remained relatively constant; this is true of the HIV
budget of the CDC.5
Under any circumstances, it would be important to subject these
prevention and treatment service programs to formative, process and
outcome evaluation. 6 Formative evaluation helps to ascertain whether
the service programs are culturally, linguistically and developmentally
appropriate - as well as potentially effective - for the intended
priority population being served. Process evaluation determines, in part,
whether the programs are delivered as planned. Outcome evaluation
determines whether the service programs achieve their stated behavior
change and health status goals. 7
Prevention NCPS, CDC. He received his B.A. (Anthropology and Sociology) from
Washington State University and his Masters of Public Administration from
California State University, Hayward.
1 Centers for Disease Control, HIVYAIDS Prevention Fact Book 1992 3-5.
2 SAMHSA was formerly the Alcohol, Drug Abuse and Mental Health
Administration (ADAMHA).
3 Fact Book , supra note 1.
4 Fred J. Hellinger, Forecasts of the costs of medical care for persons with HIV
1992-1995, 29 Inquiry 356 (1992) (in 1991 dollars).
5 Fact Book, note 1 supra.
6 Evaluating AIDS Prevention Programs 15-33 (Susan L. Coyle, Robert F. Boruch
& Charles F. Turner eds., expanded ed. 1991).
7 Id.; Evaluating AIDS Prevention: Contributions of Multiple Disciplines 1-6
(Laura C. Leviton, Andrea M. Hegedus & Alan Kubrin eds. 1990); and Michael
Scriven, Evaluation Thesaurus 250-251 (4th ed. 1991).
Holtgrave et al.: Economic Evaluation literature Review 31
In a constrained fiscal environment, a fourth type of evaluation,
economic, becomes especially important. 8 Drummond et al. define
economic evaluation as "the comparative analysis of alternative courses
of action in terms of both their costs and consequences." 9 In terms of
HIV and AIDS prevention and treatment service delivery, economic
evaluation means that we must look critically at different programmatic
activities, study their costs, estimate or observe their behavioral and
health benefits and decide whether the level of resources devoted to
programs are justified. In a rapid and emerging response to the HIV
epidemic, such decisions must be made by policy makers, program
managers and communities whether or not quantitative economic
evaluations are available. Presumably, economic evaluation information
would augment and improve this decision making process.
Drummond et al. describe several types of economic evaluation
analyses. 10 We focus on the three types that deal explicitly with
balancing health service costs and consequences: cost-effectiveness
analysis (CEA), cost-utility analysis (CUA), and cost-benefit analysis
(CBA). CEA refers to a comparison of a service program's cost with its
consequences where the consequences are expressed in some natural
units (such as "years of life saved"). CUA involves a comparison of
program cost with consequences wherein the consequences are adjusted
for their utility or quality. The most commonly measured
programmatic consequence in a CUA is the "quality-adjusted life year"
or "QALY." CBA denotes a comparison of program cost with
consequences that have been valued in money terms. For example, a
CBA might involve estimating the costs of an HIV service program,
calculating the potential number of HIV infections to be averted,
attaching a dollar value to each averted HIV infection and comparing
the programmatic costs with the monetized benefits.
8 Allan S. Detsky & I. Gary Naglie, A Clinician's Guide to Cost-Effectiveness
Analysis, 113 Ann. Intern. Med. 147 (1990) and David Eddy, Applying Cost-
Effectiveness Analysis, 268 JAMA 2575 (1992).
9 Michael F. Drummond, Greg L. Stoddart & George W. Torrance, Methods for
the Economic Evaluation of Health Care Programmes 8 (1987).
10 Id at 5-17.
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Given the extant need to compare the costs and consequences of
HIV and AIDS prevention and treatment programs, we reviewed
relevant, published CEAs, CUAs and CBAs. Our objectives were to:
present a taxonomy of major HIV-related prevention and treatment
services - and determine which of those have been subjected to formal
economic evaluation; present a taxonomy of the outcome measures that
may be used in economic evaluations - and determine which of those
have been used in previous analyses; and assess the methodological
quality of extant economic evaluations. It should be emphasized that
this review focuses only on economic evaluations; a review of all
outcome evaluations (that are important and may or may not include
economic considerations) is beyond the scope of this paper.
Methods
Taxonomy Development
Before starting a formal literature search, the authors developed a
comprehensive taxonomy of HIV and AIDS-related prevention and
treatment services. It is presented in Appendix B and contains as a
special case the sixteen-category taxonomy of AIDS policy issues
developed by Brandeau et al.1 1 It encompasses, but is not limited to,
all major types of HIV prevention programs funded by CDC and
includes common clinical treatment services. Of course, any taxonomy
of HIV and AIDS-related prevention and treatment services should be
considered "dynamic" and subject to rapid change as new services and
interventions are developed and become available.
Another taxonomy was needed to categorize outcome measures
used in the CEA/CUA/CBA studies. In this case, an entirely
satisfactory taxonomy already existed. Coyle et al. listed possible
evaluation outcome measures for HIV and AIDS-related studies. 12
These included biological, behavioral and psychological outcomes as
the three major categories.
11 Margaret L. Brandeau et al., Policy Analysis of Human Immunodeficiency Virus
Screening and Intervention: An Overview of Modeling Approaches, 5 AIDS -& Pub.
Pol.J. 119 (1990).
12 Evaluating AIDS Prevention Programs, supra note 6.
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Study Identification
Several methods were used to identify candidate studies for
inclusion into the literature review. Electronic searches were conducted
twice in calendar year 1992 in AIDSLINE. The AIDSLINE searches
included all years available in that database. The primary keywords
used included "cost-effectiveness" and "cost-benefit analysis." All
resultant references were examined. As a secondary check on the
primary electronic searches, the more general keyword ccevaluation" was
also used in AIDSLINE.
Additionally, hand reference tracing was done to determine if the
studies found via electronic searching might contain citations to other
relevant papers. Hand searching was also done on the published
abstracts for the 1991 and 1992 International Conferences on AIDS, as
well as for the last five years of Society for Medical Decision Making
Annual Conferences. The recency of the International Conferences on
AIDS, and the particular publication format of the abstracts from the
Society for Medical Decision Making Annual Conferences made them
problematic to access via AIDSLINE. Moreover, we hand searched an
economic evaluation bibliography 13 - designed to include many of
the health-related economic evaluations published - for any HIV and
AIDS-related references. We also examined for relevant references
monthly current issues of ATIN: AIDS Targeted Information.1
4
Finally, we informally queried colleagues working on HIV-related
economic evaluations to obtain still more relevant articles.
Study Selection
Studies were included if they met the following four criteria. First,
the study was a published abstract, chapter or article. Second, the
reference contained a description of an HIV or AIDS-related
prevention or treatment service. Third, the paper contained a
quantitative statement of the cost of the identified prevention or
treatment program and a quantitative statement of the consequences
13 Martin E. Backhouse, Rebecca J. Backhouse & Sally A. Edey, Economic
Evaluation Bibliography, 1(Suppl.) Health Econ. S.1-S.236 (1992).
14 A publication of abstracts and critical commentary taken from recent AIDS
literature.
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(i.e., effectiveness, utility or benefit of the program). Fourth, the paper
contained a direct quantitative comparison of the programmatic cost to
the consequences (usually via the reporting of a cost-effectiveness, cost-
utility or cost-benefit ratio). We believe that these inclusion criteria
constitute a minimal check on the quality of the examined references.
Exclusion criteria were also used. First, if a research team had
presented their work at a conference and then published a complete
report in a journal, we omitted the original conference abstract. Second,
we omitted news articles and letters-to-editors. Third, unpublished
papers provided by colleagues were excluded. Fourth, we omitted
references that dealt with alternative methods of performing HIV-
related laboratory procedures (e.g., methods for pooling sera) because
they do not directly evaluate a prevention or treatment service. Last, we
omitted papers that dealt with only the estimation of the cost or
consequences of a program (but not both)15.
Data Extraction
The following data were extracted from each study which met
inclusion (and did not meet the exclusion) criteria described above:
complete bibliographic information; taxonomic service category;
method of economic evaluation used and outcome measure used.
Information was extracted by the first author and concurrence was
obtained with the other authors; however, a quantitative study of
reliability was not attempted.
Results
Over 277 references were initially found and examined. This
included 115 from primary electronic searches; of these references, 52
referred to meeting abstracts and 63 to articles, news reports or
editorial letters. Sixty-one abstracts from the 1991 International
Conference on AIDS were hand searched (all abstracts indexed under
any keyword related to cost). Over 93 abstracts from the 1992
International Conference on AIDS were hand searched (all abstracts
relating to evaluation or cost). Eight more relevant references were
15 Several of these addressed socioeconomic impacts of HIV and AIDS.
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located via secondary electronic searches, hand searches of all abstracts
for the Society for Medical Decision Making Annual Conferences for
the last five years, other reference tracing and informal professional
networking.
Of the references initially examined, 47 met the inclusion (and no
exclusion) criteria. Our search was apparently quite comprehensive
because a section on "infectious and parasitic diseases" in a recently-
published economic evaluation bibliography would have yielded only
ten studies for inclusion.1
6
The 47 references appear in Appendix A, including 27 CEAs, 15
CBAs and five CUAs. Table 1 shows that 83% of these studies were
published in 1990 or later.
Table 1










Table 2 presents the presentation or publication outlet of the
references. Only thirteen are meeting abstracts; this may indicate that
the inclusion criteria (requiring quantitative statements of costs,
consequences, and comparisons of costs and consequences) are biased
against the brief nature of abstracts.
16 Supra note 13.
5 Risl Health, Safety & Environment 29 [Winter 1994]
Table 2
Presentation and Publication Outlets
Outlet Reference Count
Society for Medical Decision Making Conferences 4




All 47 references included (observed or estimated) biological
outcomes. That is, none were solely focused on behavioral or
psychological outcome measures. Therefore, the biological outcome





HIV infections averted 15
HIV infections identified 12
Years of life saved 5
Quality-adjusted life years saved 5
AIDS cases averted 3
Opportunistic infections averted (general) 1
Pneumocystis carinii pneumonia cases averted 1
Pneumocystis carinii pneumonia relapses averted 1
Other 4
Total 47
Table 3 displays the numbers of studies in each biological outcome
measure subcategory. The most frequently used, primary outcome
measure is "HIV infections averted" as a consequence of the analyzed
program. The second most frequent is "HIV infections identified."
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Many articles that deal with partner notification or screening programs
use this outcome measure as a primary aspect of analysis.
Appendix B displays the HIV and AIDS prevention and treatment
service taxonomy developed a priori; it also contains relevant reference
numbers from Appendix A for each service category. It is readily
apparent from Appendix B that only about one-quarter of prevention
and treatment services have been subjected to formal economic
evaluation. Service categories that have been analyzed are summarized
in Table 4. Of these 47 references, 38% deal with some type of HIV
screening program, 34% with some type of clinical prevention or
medical service and 13% with partner notification programs.
Table 4
HIV Prevention and Treatment Services Subjected to Economic Evaluation
(Summary)
Service Reference Count
Mandatory counseling and testing, and other screening 18
Partner notification 6
Other counseling, testing, referral and partner notification 2
Pneumocystis carinii pneumonia prophylaxis 5
Anti-retroviral (therapeutic) 4
Anti-retroviral (post-exposure prophylaxis) 2
Other treatment (medical) 4
Other treatment (medical and psychosocial) 1




The formal economic evaluation of HIV and AIDS prevention and
treatment services is reflected in a rapidly expanding literature.
Although over 277 references were examined for potential inclusion in
this literature review, only 47 met basic inclusion criteria and quality
checks. Still, the inclusion criteria used may have reflected a bias against
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abstracts which are necessarily brief in nature. Given the large number
of abstract references examined but excluded, it may be that many of
these abstract authors soon will be publishing their work as more
detailed journal articles (the detail of which would make them more
likely to meet our inclusion criteria).
It is interesting that no study made behavioral or psychological
outcome measures its primary outcome measure. This may be due to
the difficulty of developing a behavioral or psychological outcome
measure that is appropriate for such evaluations. Brandeau et al. have
called for the development of more comprehensive behavioral outcome
measures for use in AIDS policy analyses. 17 Alternatively, the lack of
psychological or behavioral primary outcome measures may be due to a
perceived need to convert behavioral phenomenon into biological
measures to justify what are, after all, health-related services programs.
Since many of the HIV and AIDS-related prevention and treatment
services described in Appendix B aim to change behavior as a way to
influence health status, the evaluation of such programs takes on an
added and difficult dimension that is not present in the economic
evaluation of strictly curative medical interventions related to some
other health problems.
For most HIV prevention programs, a thorough economic
evaluation requires the observation or estimation of the cost of program
implementation, an assessment of the behavioral impact, a mapping of
the behavioral changes into changes in biological outcomes and health
status and a comparison of health status consequences with the cost of
program implementation. This can be contrasted with the economic
evaluation, in another health-related arena, of two different methods
for fluid resuscitation; 18 in such an evaluation, the intermediate steps
of behavior change assessment and mapping of behavior change to
health outcomes are not needed whatsoever. Although behavior change
must be assessed in the economic evaluation of other health-related
prevention programs such as the North Karelia Project for the
17 Supra note 11.
18 Roberto Bisonni et al., Colloids Versus Crystalloids in Fluid Resuscitation, 32 J.
Fan. Practice 387 (1991).
Holtgrave et al.: Economic Evaluation literature Review 39
prevention of cardiovascular disease, 19 HIV-related sexual and drug
use behaviors are sensitive in nature and relatively difficult to measure.
This makes the economic evaluation of HIV prevention pr6grams
particularly challenging.
Appendix B supports the proposition that little is known about the
relative cost-effectiveness of several categories of HIV-related service
programs. Yet, there are three historically plausible reasons. First, not
until the last decade did HIV infection came onto the public health
horizon. It has been only the in the last few years that many of the
services listed in Appendix B came into 'being. For instance, HIV-
related community level interventions have only recently become a
priority prevention activity.20 Hence, there simply has not been time
to subject some of these programs to rigorous economic evaluation.
Another historical reason is that the collection of detailed cost data
on new services is difficult and takes time to implement. Cost analysis
studies and data collection systems must be designed, staff trained in
cost analytic procedures, and cost data collected and analyzed.
Therefore, some of the more recently-developed HIV prevention and
treatment services are just now being subjected to basic cost-analyses;
more complete economic evaluations (i.e., CEAs, CBAs and CUAs)
will follow. As these cost analyses are conducted, they could be
published routinely as part of evaluation study reports (however, this
would be a new type of publication for many journals).
A third historical reason is that economic evaluation techniques
seem to be used once an area of health service delivery has existed for
an extended period of time. Indeed, they have long been used in
clinical medicine but are only now beginning to see wide-spread
popularity in the public health arena. This may suggest a reason why so
many of the economic evaluations included in our literature review were
focused on clinical AIDS management topics. However, this historically
plausible reasoning should not prevent the providers of HIV prevention
19 Stephen R. Engleman & John F. Forbes, Economic Aspects of Health
Education, 22 Soc. Sci. Med. 443 (1986).
20 Centers for Disease Control, Cooperative Agreements for Human
Immunodeficiency Virus (HIV): Prevention Projects Program Announcement and
Availability of Funds for Fiscal Year 1993, 57 Fed. Reg. 40,675 (1992).
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services from now performing much needed economic evaluations.
Further, economic evaluation modelling techniques can be used even
before a health services program is widely implemented to estimate the
potential cost-effectiveness of the planned program; hence, there is no
theoretical reason why economic evaluation techniques cannot be used
throughout the planning, implementation and modification of health
services programs.
Besides needing more economic evaluations of the service eategories
in our taxonomy, policy makers and program managers also need
economic evaluations of new categories as they become available (e.g.,
needle and syringe exchange services; community planning and
development efforts; and educational methods that use emerging
technologies to deliver services). Further, methods should be developed
for determining when a'service category has received sufficient
economic evaluation. For instance, few would argue the merits of
screening programs for donated blood.
In this paper, we have resisted the temptation to provide a table of
CEA, CUA, or CBA ratios from the 47 included studies which might
be used to state which analyzed services are most "cost-effective." To
provide such a table at this point in the development of the HIV and
AIDS economic evaluation literature would seem to be a mistake.
These 47 papers differ so greatly in terms of particular evaluation
methodologies used (e.g., methods to assess quality of life), biological
outcome measure subcategories used, and services examined, that
comparison among them is problematic. To summarize the base case
results of these 47 studies in a table would be analogous to prematurely
combining studies in a meta-analysis.2 1 Rather, it is our hope that
persons interested in such comparisons will use our review to guide
them to relevant literature which they will then dissect carefully in
terms of methodological study differences before comparing HIV and
AIDS prevention and treatment services to each other.
21 K. Dickersin & J. A. Berlin, Meta-Analysis: State-of-the-Science, 14 Epidem.
Revs. 154 (1992).
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Used in such a way, the studies cited in this review might inform
program management and policy debates on specific decisions.
However, it should be stressed again that programmatic and policy
decisions about HIV and AIDS-related prevention and treatment
programs necessarily are made continually. These decisions must be
made in response to an epidemic and cannot wait. Although many
programs are based on well-accepted standards for health promotion
programs, quantitative economic evaluations can inform, and
presumably improve this decision making. Hence, analysts doing HIV
and AIDS-related economic evaluations must "catch up" to the urgent
decisions which must be made; decision processes (usually) cannot be
slowed down to wait for comprehensive economic analyses to be
completed.
Another indication that the economic evaluation of HIV and AIDS
related services is in its early stages (relative to that for other health
problems) is that only five of the 47 included articles incorporated
quality of life considerations. The QALY outcome measure is used
whenever possible in health-related economic evaluations because it
should, in principle, allow for consideration of multiple factors that
influence perceived quality of life - and the comparison of multiple
health-related programs to each other on a common basis (i.e., cost-
per-QALY).22
A historical explanation for this relative lack of HIV-related CUA
studies seems plausible. In order to perform a CUA, one must be able
to estimate quality of life for those persons suffering from the. particular
health problem (here, HIV infection and AIDS). Therefore, quality of
life estimation studies are likely to precede CUAs in the literature; only
recently have such quality of life estimation studies been seen in the
HIV and AIDS literature. 2 3 So it seems that the relative number of
22 Harold C. Sox et al., Medical Decision Making 201-237 (1988).
23 Albert W. Wu et al., Quality of Life in a Placebo-Controlled Trial of
Zidovudine in Patients with AIDS and AIDS-Related Complex, 3 J. Acquir.
Immune Defic. Syndr. 683 (1990); Robert M. Kaplan et al., The Quality of Well-
Being Scale: Applications in AIDS, Cystic Fibrosis, and Arthritis, 27(3 Suppl.) Med.
Care S.27 (1989); and Diane Ragsdale & James R. Morrow, Quality of Life as a
Function of HIV Classification, 39 Nurs. Resh. 355 (1990).
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CUA economic evaluations of HIV and AIDS service programs is likely
to increase as the rather new HIV and AIDS quality of life assessment
literature burgeons. These CUAs are important for comparing the HIV
and AIDS-related services to other health care programmes since the
quality-adjusted life year is an outcome often used to compare the,
cost-utility of programs across health arenas.
In summary, review of the rapidly expanding literature revealed
that: most HIV prevention and treatment service categories have not
yet been subjected to economic evaluation; behavioral outcome
measures have not been the sole focus of any examined economic
evaluation; and the majority of references examined lacked formal
quantitative analyses. Much greater effort is needed in conducting and
publishing rigorous economic evaluations of HIV and AIDS prevention
and treatment programs - in the timely fashion required for urgent
policy and program management decisions (especially concerning
resource allocation) attempting to halt the HIV epidemic.
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References Ilncuded in Literature Review
Al. Upton D. Allen, Stanley Read & Amiram Gafni, Zidovudine for
Chemoprophylaxis after Occupational Exposure to HIV-Infected Blood: An
Economic Evaluation, 14 Clin. Infect. Dis. 822 (1992).
A2. C. Cameron et al., Prevention Scenarios: Swiss AIDS Programme, VI Int'l Conf.
AIDS, San Francisco, June 1990 [abs. FD834].
A3. Niccie L. McKay & Kristen M Phillips, An Economic Evaluation of Mandatory
Premarital Testing for HIV, 28 Inquiry 236 (1991).
A4. S. Forsythe et al., Measuring Costs and Benefits of Targeted Condom
Distribution Programs in Latin American and Caribbean Countries, VIII Int'l Conf.
AIDS, Amsterdam, July 1992 [abs. POD5403.
A5. E.A. de Moya et al., Measuring the Costs and Benefits of HIV Screening
Systems in Trinidad and Tobago, the Dominican Republic and the Philippines, VIII
Int'l Conf. AIDS, Amsterdam, July 1992 [abs. POD5402].
A6. David R. Holtgrave et al., Human Immunodeficiency Virus Counseling,
Testing, Referral and Partner Notification Services: A Cost-Benefit Analysis, 153
Arch. Intern. Med. 1225 (1993).
A7. Milton C. Weinstein et al., Cost-Effectiveness Analysis of AIDS Prevention
Programs: Concepts, Complications and Illustrations, in AIDS: Sexual Behavior and
Intravenous Drug Use 471 (C.F. Turner, H. G. Miller & L.E. Moses eds. 1989).
A8. Bernard J. Turnock & Chester J. Kelly, Mandatory Premarital Testing for
Human Immunodeficiency Virus: The Illinois Experience, 261 JAMA 3415 (1989).
Holtgrave et al.: Economic Evaluation literature Review 43
A9. Paul D. Cleary et al., Compulsory Premarital Screening for the Human
Immunodeficiehcy Virus, 258 JAMA 1757 (1987).
A10. Ronald Altman et al., Premarital HIV-1 Testing in New Jersey, 5 J. Acquir.
Immune Defic. Syndr. 7 (1992).
All. John F. Johanson & Amnon Sonnenberg, Efficient Management of Diarrhea in
the Acquired Immunodeficiency Syndrome (AIDS): A Medical Decision Analysis,
112 Ann. Intern. Med. 942 (1990).
A12. Stephen Crystal et al., AIDS Contact Notification: Initial Program Results in
New Jersey, 2 AIDS Educ. Prey. 284 (1990).
A13. Stephen Moses et al., Controlling HIV in Africa: Effectiveness and Cost of an
Intervention in a High-Frequency STD Transmitter Core Group, 5 AIDS 407
(1991).
A14. N. Spencer, C. Raevsky & F. Wolf, Results and Benefit-Cost Analysis of
Provider-Assisted HIV Partner Notification and Referral, V Int'l Conf." AIDS,
Montreal, June 1989 [abs. WAO21].
Al 5. G. Fulop et al., Scatter Bed Versus Cluster Unit Treatment of AIDS Inpatients,
V Int'l Conf. AIDS, Montreal, June 1989 [abs. THP7I.
A16. T. W. Cheung, M. Fahs & H. S. Sacks, Cost-Effectiveness Analysis of Early
Treatment of HIV Disease with Zidovudine (AZT), VI Int'l Conf. AIDS, San
Francisco, June 1990 [abs. 4078].
A17. W. C. Mathews et al., Cost-Effectiveness of Secondary PCP Prophylaxis Using
Aerosolized Pentamidine: Evaluation of a Hospital-Based Program, VI Int'l Conf.
AIDS, San Francisco, June 1990 [abs. 2088].
A18.M. D. Smith et al., Cost-effectiveness of Aerosolized Pentamidine (AP)
Prophylaxis Against Pneumocystis Carinii Pneumonia, VI Int'l Conf. AIDS, San
Francisco, June 1990 [abs. FD830].
A19. M. L. DeCiantis et al., Routine HIV Testing in an Acute Care Hospital
Inpatient Setting, VI Int'l Conf. AIDS, San Francisco, June 1990 [abs. THD826].
A20. George W. Rutherford et al., Partner Notification and the Control of Human
Immunodeficiency Virus Infection, 18 Sex. Transm. Dis. 107 (1991).
A21. Susan R. Stock, Amiram Gafni & Ralph F. Block, Universal Precautions to
Prevent HIV Transmission to Health Care Workers: An Economic Analysis, 142
Can. Med. Assoc. J. 937 (1990).
A22. Kenneth'A.. Freedberg et al., Primary Prophylaxis for Pneumocystis Carinii
Pneumonia in HIV-Infected People with CD4 Counts below 200/mm3 : A Cost-
Effectiveness* Analysis, 4 J. Acquir. Immune. Defic. Syndr. 521 (1991).
A23. Kevin A. Schulman et al., Cost Effectiveness of Low-Dose Zidovudine Therapy
for Asymptomatic Patients with Human Immunodeficiency Virus (HIV Infection,
114 Ann. Intern. Med. 798 (1991).
A24. Abel R. Castellano & Mary D. Nettleman, Cost and Benefit of Secondary
Prophylaxis for Pneumocystis Carinii Pneumonia, 266 JAMA 820 (1991).
A25. A. David Paltiel & Edward H. Kaplan, Modeling Zidovudine Therapy: A
Cost-Effectiveness Analysis, 4 J. Acquir. Immune. Defic. Syndr. 795 (1991).
5 Risk: Health, Safety & Environment 29 [Wimter 1994]
A26. Mitchell H. Gail, Dale Preston & Steve Piantadosi, Disease Prevention Models
of Voluntary Confidential Screening for Human Immunodeficiency Virus (HM, 8
tat. Med. 59 (1989).
A27. Richard S. Eisenstaedt & Thomas E. Getzen, Screening Blood Donors for
Human Immunodeficiency Virus Antibody: Cost-Benefit Analysis, 78 Am. J. Pub.
H. 450 (1988).
A28. Daniel N. Mendelson & S. Gerald Sandier, A Model for Estimating
Incremental Benefits and Costs of Testing Donated Blood for Human
Immunodeficiency Virus Antigen (HIV-Ag), 30 Transfusion 73 (1990).
A29. Richard L. Harris et al., Evaluation of a Hospital Admission HIV Antibody
Voluntary Screening Program, 11 Infect. Control Hosp. Epidemiol. 628 (1990).
A30. C. LeGales & J. P Moatti, Cost-Effectiveness of HIV Screening of Pregnant
Women in Hospitals of the Paris Area, 37 Eur. J. Obstet. Gynecol. Reprod. Biol. 25
(1990).
A31. Franklyn N. Judson, Partner Notification for HIV Control, 25 Hosp. Practice
63 (1990).
A32. Steven Nahmias & Charles D. Feinstein, Screening Strategies to Inhibit the
Spread of AIDS, 24 Socioecon. Plan. Sci. 249 (1990).
A33. Abdolazim Houshyar, Screening Pregnant Women for HIV Antibody: Cost-
Benefit Analysis, 6 AIDS & Pub. Pol. J. 98 (1991).
A34, Scott D. Ramsey & Mary D. Nettleman, Cost-Effectiveness of Prophylactic
AZT Following Needlestick Injury in Health Care Workers, 12 Med. Decis. Making
142 (1992).
A35. Hanna Zowall et al., HIV Antibody Screening among Immigrants: A Cost-
Benefit Analysis, 143 Can. Med. Assoc. J. 101 (1990).
A36. David E. Bloom & Sherry Glied, Benefits and Costs of HIV Testing, 252
Science 1798 (1991).
A37. Lyle R. Petersen, Carol R. White & Premarital Screening Study Group,
Premarital Screening for Antibodies to Human Immunodeficiency Virus Type 1 in
the United States, 80 Am. J. Pub. H. 1087 (1990).
A38. Johan Geisecke et al., Efficacy of Partner Notification for HIV Infection, 338
Lancet 1096 (1991).
A39. Randolph F. Wykoff et al., Contact Tracing to Identify Human
Immunodeficiency Virus Infection in a Rural Community, 259 JAMA 3563 (1988).
A40. Kenneth, A. Freedberg et al., Optimal Management Strategies for HIV-
Infected Patients Who Present with Cough or Dyspnea: A Cost-Effectiveness
Analysis, 7 J. Gen. Intern. Med. 261 (1992).
A41. M. J. Buxton et al., Cost Implications of Alternative Treatments for AIDS
Patients with Cryptococcal Meningitis: Comparison of Fluconazole and
Amphotericin B-Based Therapies, 23 J. Infect. 17 (1991).
A42. B. D. McCarthy, J. B. Wong & F. A. Sonnenberg, Cost-Effectiveness of
Screening for Asymptomatic HIV Infection, Twelfth Ann. Conf. Soc'y Medical
Decision Making, Boston, Nov. 1990. Abstract, 10 Med. Decis. Making 329 (1990).
A43. P. Cowper et al., Factors Influencing the Cost-Effectiveness of Early Versus
Later Zidovudine (AZT) Treatment of Symptomatic Human Immunodeficiency
Holtgrave et al.: Economic Evaluation Literature Review 45
Virus Infection. Fourteenth Ann. Conf. Soc' Medical Decision Making, Portland
OR, Oct. 1992. Abstract, 12 Med. Decis. Making 340 (1992).
A44. K. A. Freedberg, C. J. Cohen & T. W Barber, Preventing Mycobacterium
Avium Complex Infection in Patients with AIDS: A Cost-Effectiveness Analysis,
Fourteenth Ann. Conf. Soc'y Medical Decision Making, Portland OR, Oct. 1992.
Abstract, 12 Med. Decis. Making 339 (1992).
A45. J. C Healy, S. A. Frankforter & B. K. Graves, Autologous Predeposit in Total
Hip Arthroplasty: A Cost-Effectiveness Analysis, Fourteenth Ann. Conf. Soc'y
Medical Decision Making, Portland OR, Oct. 1992. Abstract, 12 Med. Decis.
Making 339 (1992).
A46. Margaret L. Brandeau et al., Screening Women of Childbearing Age for
Human Immunodeficiency Virus: A Cost-Benefit Analysis, 152 Arch. Intern. Med.
2229 (1992).
A47. Andrea Tramarin et al., An Economic Evaluation of Home-Care Assistance for
AIDS Patients: A Pilot Study in a Town in Northern Italy, 6 AIDS 1377 (1992).
Appendix B
Taxonomy of HIV Prevention and Treatment Services
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1. Counseling, testing, referral and partner notification [A6]




c. prisons (where required by law)
d. insurance
e. sexual assault (where required by law)
f. pre-marital (where required by law) [A3, A7, A8, A9, Al 0, A37]
g. blood bank screening [A5, A27, A28]
h. hospital patients (where required by institutional policy)
[A19, A29, A301
i. general "screening" [A32, A42]
J. immigrants [A35]
k. job applicants (where required by institutional policy) [A36]
ii. voluntary testing
a. determine own serostatus (personal risk assessment) [A26]
(1) clinic setting
(a) persons in STD clinics
(b) persons in drug treatment
(c) persons in TB clinics
(d) persons in family planning clinics
(e) other clinic setting (e.g., private physician)
(2) community setting (e.g., the street; community organizations)
b. perinatal screening [A33, A46]
c. enhanced/repeated post-test counseling in any setting
d. enhanced efforts at increasing rate of return for post-test
counseling in any setting
24 References are to Appendix A.
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iii. alternative methods of testing
a. saliva testing
b. urine testing
c. dried bloodspot testing
d. rapid testing, other
iv. alternative methods of pre- and post-test counseling
B. Referral
i. referral verification systems
ii. staff assisted referrals
iii. decentralized vs centralized case management
iv. linking outreach programs to clinic-based CT services
C. Partner notification
i. provider referral [A14, A31]
ii. patient referral
ii. mixed strategies (A12, A20, A38, A39]
iv. couples counseling
v. special referral systems for partners
D. Other
i. staff training
ii. quality assurance programs
iii. STD treatment as a strategy for HIV prevention
iv. condom distribution in STD clinics




(1) condom use training
(2) negotiation of safer sexual behaviqrs
b. other psychosocial issues
ii. non-peer counselor
a. skills training
(1) condom use training
(2) negotiation of safer sexual behaviors




(1) condom use training
(2) negotiation of safer sexual behaviors
b. other psychosocial issues
ii. non-peer mediated
a. skills training
(1) condom use training
(2) negotiation of safer sexual behaviors
b. other psychosocial issues




iv. condom distribution and promotion [A4, A13]
v. bleach distribution
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D. School-based programs
i. peer led
ii. teacher (or other non-peer) led
iii. as part of comprehensive health education program
iv. condom distribution
E. Worksite health promotion
i. peer led
ii. non-peer led





i. print mass media
ii. electronic mass media
B. Other printed media
i. small media





i. prophylaxis for Pneumocystis carinii pneumonia (PCP) [A17, A18, A
A24, A401
ii. anti-retroviral therapy
a. post-exposure prophylaxis [Al, A34]
b. therapeutic [Al 6, A23, A25, A43]
iii. treatment of opportunistic infections other than PCP [A41,
iv. treatment of HIV-associated malignancies
v. treatment of other conditions [All, A15]
5. Minority/youth/womens' initiatives (See substantive programmaticareas above)
6. Other
A. Community development (including private/public ventures)
B. Multi-year funding of projects
C. Formula grants
D. Funding national organizations to provide technical assistance
E. Occupational transmission (not related to AZT) [A21]
F. Other [A2, A45]
,22,
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